Trial Summary
The trial information does not specify whether you need to stop taking your current medications.
Moxidectin has shown strong effectiveness in treating various parasitic infections in humans and animals, such as onchocerciasis and gastrointestinal nematodes, with significant reductions in parasite counts and long-lasting effects. While this data does not directly address blepharitis, it suggests moxidectin's potential as a powerful antiparasitic agent.
12345Moxidectin has been studied in humans and is generally considered safe and well-tolerated at doses between 3 mg and 36 mg, with some mild to moderate side effects like headaches and dizziness. No serious adverse events were reported in these studies.
16789Moxidectin is unique for treating blepharitis because it is primarily known as an antiparasitic drug, which suggests it may work differently from other treatments like tobramycin dexamethasone or bibrocathol ointments that are more commonly used for this condition.
1011121314Eligibility Criteria
This trial is for individuals with active blepharitis, characterized by eyelid inflammation and debris (collarettes) around the lashes. It's not suitable for those with other significant eye diseases.Inclusion Criteria
Exclusion Criteria